Tenax Therapeutics (TENX) Change in Accured Expenses (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Change in Accured Expenses of -$862000.0 for Q2 2026, down 183.2% year-over-year from $1.0 million in Q2 2025, and down 184.1% on a QoQ basis from $1.0 million in Q1 2026.
Tenax Therapeutics (TENX) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$862000.0 in Q2 2026.
- Change in Accured Expenses for Q2 2026 came in at -$862000.0, down 183.2% year-over-year; the trailing twelve-month figure through Jun 2026 was -$687000.0 (down 150.11% YoY), and the FY2025 annual result was -$421000.0, down 180.5% from the prior year.
- Change in Accured Expenses retreated to -$862000.0 in Q2 2026, from $1.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.0 million in Q2 2025 and troughed at -$974000.0 in Q3 2025.
- A 5-year average of $8724.9 and a median of -$794.5 in 2023 frame the typical range for Change in Accured Expenses.
- The widest annual swing landed in 2023, when Change in Accured Expenses plunged 442.26%; it then surged 1717.54% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $529205.0 in 2022, then jumped by 89.48% to $1.0 million in 2023, then tumbled by 44.45% to $557000.0 in 2024, then plunged by 77.74% to $124000.0 in 2025, then plunged by 795.16% to -$862000.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$862000.0 in Q2 2026, $1.0 million in Q1 2026, and $124000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | -862,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -862,000.00 |
| Jun 30, 2026 | -862,000.00 |
| Mar 31, 2026 | 1.03 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 124,000.00 |
| Dec 31, 2025 | 124,000.00 |
| Sep 30, 2025 | -974,000.00 |
| Sep 30, 2025 | -974,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | -607,000.00 |
| Mar 31, 2025 | -607,000.00 |
| Dec 31, 2024 | 557,000.00 |
| Dec 31, 2024 | 557,000.00 |
| Sep 30, 2024 | 385,000.00 |
| Sep 30, 2024 | 385,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | -476,000.00 |
| Mar 31, 2024 | -476,000.00 |